2021-002795-39
A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptomatic knee osteoarthritis
Novartis Farmacéutica S.A.·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Knee osteoarthritis
Sponsor & location
- Primary sponsor
- Novartis Farmacéutica S.A.
- Funder
- Novartis Pharma AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
•Painful ipsilateral hip OA defined as a Pain NRS >/3 on the majority of days in the last 3 months prior to Screening 1, as reported by the patient.
ICD-10 classifications
Chronic instability of kneeGonarthrosis [arthrosis of knee]Other hypertrophic osteoarthropathyDislocation, sprain and strain of joints and ligaments of kneePatellofemoral disorders
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2021-002795-39
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2021-002795-39 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Farmacéutica S.A. and is currently Ongoing. The study focuses on Knee osteoarthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.